Opioid Induced Constipation Drugs Market Share and Growth Analysis 2034
Global Opioid Induced Constipation Drugs Market Growth, Size, Trends Analysis - By Drug Class, By Prescription, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25203 | Pages: 1 - 250 | Formats*: |
| Category : Healthcare | |||
Global Opioid Induced Constipation Drugs Market Introduction and Overview
According to SPER Market Research, the Global Opioid Induced Constipation Drugs Market is estimated to reach USD 3.61 billion by 2034 with a CAGR of 5.06%.
The report includes an in-depth analysis of the Global Opioid Induced Constipation Drugs Market, including market size and trends, product mix, Applications, and supplier analysis. The rising use of opioids, alongside an increasing prevalence of gastrointestinal disorders, has intensified the demand for effective treatments like opioid-induced constipation (OIC) drugs. As more patients rely on opioids for pain management, awareness of their side effects—particularly constipation—has grown. This has led to a surge in individuals seeking relief from OIC symptoms. Consequently, the expanding population affected by opioid-related gastrointestinal issues is fueling the need for targeted pharmaceutical solutions. OIC drugs play a critical role in addressing these concerns, significantly driving market growth in this therapeutic area. However, The opioid-induced constipation (OIC) drugs market faces challenges such as high drug costs and limited patient awareness about treatment options. Additionally, regulatory hurdles and potential side effects of OIC medications can restrict market growth.
By Drug Class:
The opioid-induced constipation drugs market is segmented by drug class into categories such as PAMORAs, chloride channel-2 activators, laxatives, proton pump inhibitors, anti-diarrheals, and others. Among these, peripherally acting mu-opioid receptor agonists (PAMORAs) hold a significant share due to their targeted mechanism of action. PAMORAs are specifically designed to treat constipation caused by opioid use by acting on peripheral mu-opioid receptors in the gastrointestinal tract, without affecting the pain-relieving benefits of opioids. This targeted approach not only ensures effective relief from constipation but also improves overall bowel function and patient satisfaction, making PAMORAs a key growth driver in the coming years.
By Prescription Type:
The opioid-induced constipation drugs market is divided into prescribed and over-the-counter (OTC) drugs, with prescribed drugs holding a dominant position. This reflects the preference for targeted, clinically validated treatments that effectively address gastrointestinal issues caused by opioid use. Healthcare professionals frequently recommend prescription medications like naloxegol, lubiprostone, and naldemedine, which are proven to relieve OIC symptoms. The effectiveness and widespread use of these therapies reinforce the essential role of prescription drugs in managing OIC, contributing significantly to the segment's continued growth.
By Route of Administration:
The opioid-induced constipation drugs market is divided by route of administration into oral and injectable types, with oral medications contributing significantly to the market’s expansion. Oral medications offer a convenient, non-invasive solution that aligns with patient preferences, leading to better adherence and improved treatment outcomes. The wide variety of oral therapeutic options allows for personalized treatment plans tailored to individual needs. This versatility and ease of use enhance the effectiveness of OIC management, reinforcing the importance of oral drugs in the treatment landscape.
By Distribution Channel:
The opioid-induced constipation drugs market is categorized by distribution channels into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies dominating the segment. These pharmacies serve as key points for dispensing prescribed medications directly to patients receiving treatment, ensuring timely access to opioid-induced constipation therapies. Their close integration with patient care enhances their role in OIC drug distribution. Additionally, hospital pharmacies are equipped with proper storage facilities and follow stringent regulatory standards, ensuring the safety, stability, and effectiveness of medications, which further strengthens their position in the overall distribution network.
By Regional Insights
North America holds a leading position in the opioid-induced constipation drugs market, driven by its advanced healthcare infrastructure and strong focus on comprehensive patient care. The region is well-equipped to address opioid-related complications, including the need for effective treatments for constipation, which supports growing demand for OIC medications. Additionally, the increasing prevalence of gastrointestinal disorders across North America intensifies the burden of opioid-induced constipation. The overlap of these conditions highlights the need for targeted pharmaceutical solutions, reinforcing the demand for OIC drugs and contributing to ongoing market growth in the region.
Market Competitive Landscape
The market for Global Opioid Induced Constipation Drugs Market is highly consolidated. Some of the key market players are Atlantis Consumer Healthcare Inc., Bausch Health Companies Inc., Bayer AG, Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Sanofi, Shionogi & Co., Ltd., Valinor Pharma, LLC.
Recent Developments:
In December 2021, Shionogi & Co., Ltd. announced the approval of Symproic in Taiwan for treating opioid-induced constipation in adult patients. Symproic, a peripherally acting mu-opioid receptor antagonist developed by Shionogi, is anticipated to help the company broaden its customer base and extend its reach into new geographic markets.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Drug Class, By Prescription, By Route of Administration, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, Middle East & Africa. |
| Companies Covered | Atlantis Consumer Healthcare Inc., Bausch Health Companies Inc., Bayer AG, Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Sanofi, Shionogi & Co., Ltd., Valinor Pharma, LLC. |
Key Topics Covered in the Report
- Global Opioid Induced Constipation Drugs Market Size (FY’2021-FY’2034)
- Overview of Global Opioid Induced Constipation Drugs Market
- Segmentation of Global Opioid Induced Constipation Drugs Market By Drug Class (Peripherally acting mu-opioid receptor agonists (PAMORAs), Chloride channel-2 activators, Laxatives, Proton pump inhibitors, Anti-diarrheal, Other drug classes)
- Segmentation of Global Opioid Induced Constipation Drugs Market By Prescription Type (Prescribed drugs, Over-the-counter (OTC) drugs)
- Segmentation of Global Opioid Induced Constipation Drugs Market By Route of Administration (Oral, Injectable)
- Segmentation of Global Opioid Induced Constipation Drugs Market By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies)
- Statistical Snap of Global Opioid Induced Constipation Drugs Market
- Expansion Analysis of Global Opioid Induced Constipation Drugs Market
- Problems and Obstacles in Global Opioid Induced Constipation Drugs Market
- Competitive Landscape in the Global Opioid Induced Constipation Drugs Market
- Details on Current Investment in Global Opioid Induced Constipation Drugs Market
- Competitive Analysis of Global Opioid Induced Constipation Drugs Market
- Prominent Players in the Global Opioid Induced Constipation Drugs Market
- SWOT Analysis of Global Opioid Induced Constipation Drugs Market
- Global Opioid Induced Constipation Drugs Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Opioid Induced Constipation Drugs Market Size Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Opioid Induced Constipation Drugs Market
7.Global Opioid Induced Constipation Drugs Market, By Drug Class 2021-2034 (USD Million)
7.1.Peripherally acting mu-opioid receptor agonists (PAMORAs)7.2.Chloride channel-2 activators7.3.Laxatives7.4.Proton pump inhibitors7.5.Anti-diarrheal7.6.Other drug classes
8.Global Opioid Induced Constipation Drugs Market, By Prescription Type 2021-2034 (USD Million)
8.1.Prescribed drugs8.2.Over-the-counter (OTC) drugs
9.Global Opioid Induced Constipation Drugs Market, By Route of Administration 2021-2034 (USD Million)
9.1.Oral9.2.Injectable
10.Global Opioid Induced Constipation Drugs Market, By Distribution Channel 2021-2034 (USD Million)
10.1.Hospital pharmacies10.2.Retail pharmacies10.3.Online pharmacies
11.Global Opioid Induced Constipation Drugs Market 2021-2034 (USD Million)
11.1.Global Opioid Induced Constipation Drugs Market Size and Market Share
12.Global Opioid Induced Constipation Drugs Market, By Region, 2021-2034 (USD Million)
12.1.Asia-Pacific
12.1.1.Australia12.1.2.China12.1.3.India12.1.4.Japan12.1.5.South Korea12.1.6.Rest of Asia-Pacific
12.2.Europe
12.2.1.France12.2.2.Germany12.2.3.Italy12.2.4.Spain12.2.5.United Kingdom12.2.6.Rest of Europe
12.3.Middle East and Africa
12.3.1.Kingdom of Saudi Arabia12.3.2.United Arab Emirates12.3.3.Qatar12.3.4.South Africa12.3.5.Egypt12.3.6.Morocco12.3.7.Nigeria12.3.8.Rest of Middle-East and Africa
12.4.North America
12.4.1.Canada12.4.2.Mexico12.4.3.United States
12.5.Latin America
12.5.1.Argentina12.5.2.Brazil12.5.3.Rest of Latin America
13.Company Profile
13.1.Atlantis Consumer Healthcare Inc.
13.1.1.Company details13.1.2.Financial outlook13.1.3.Product summary13.1.4.Recent developments
13.2.Bausch Health Companies Inc.
13.2.1.Company details13.2.2.Financial outlook13.2.3.Product summary13.2.4.Recent developments
13.3.Bayer AG
13.3.1.Company details13.3.2.Financial outlook13.3.3.Product summary13.3.4.Recent developments
13.4.Cumberland Pharmaceuticals Inc.
13.4.1.Company details13.4.2.Financial outlook13.4.3.Product summary13.4.4.Recent developments
13.5.Mallinckrodt Pharmaceuticals
13.5.1.Company details13.5.2.Financial outlook13.5.3.Product summary13.5.4.Recent developments
13.6.Sanofi
13.6.1.Company details13.6.2.Financial outlook13.6.3.Product summary13.6.4.Recent developments
13.7.Shionogi & Co., Ltd.
13.7.1.Company details13.7.2.Financial outlook13.7.3.Product summary13.7.4.Recent developments
13.8.Valinor Pharma, LLC
13.8.1.Company details13.8.2.Financial outlook13.8.3.Product summary13.8.4.Recent developments
13.9.Others
14.Conclusion
15.List of Abbreviations
16.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Opioid Induced Constipation Drugs Market is projected to reach USD 3.61 billion by 2034, growing at a CAGR of of 5.06% during the forecast period.
Opioid Induced Constipation Drugs Market grew in Market size from 2025. The Market is expected to reach USD 3.61 billion by 2034, at a CAGR of 5.06% during the forecast period.
Opioid Induced Constipation Drugs Market CAGR of 5.06% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Opioid Induced Constipation Drugs Market size is USD 3.61 billion from 2025 to 2034.
Opioid Induced Constipation Drugs Market is covered By Drug Class, By Prescription, By Route of Administration, By Distribution Channel
The North America is anticipated to have the highest Market share in the Opioid Induced Constipation Drugs Market.
Atlantis Consumer Healthcare Inc., Bausch Health Companies Inc., Bayer AG, Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Sanofi, Shionogi & Co., Ltd., Valinor Pharma, LLC.
The report includes an in-depth analysis of the Global Opioid Induced Constipation Drugs Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
